Tempus AI’s (TEM) “Buy” Rating Reiterated at Needham & Company LLC

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by research analysts at Needham & Company LLC in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $75.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 47.35% from the company’s previous close.

A number of other research analysts have also weighed in on TEM. Canaccord Genuity Group cut their price objective on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Stifel Nicolaus set a $60.00 target price on Tempus AI in a research report on Wednesday, February 25th. Morgan Stanley cut their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Finally, Piper Sandler decreased their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $78.62.

Tempus AI Stock Performance

Shares of TEM stock opened at $50.90 on Wednesday. The business has a fifty day moving average of $59.77 and a 200 day moving average of $72.20. Tempus AI has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm has a market capitalization of $9.10 billion, a price-to-earnings ratio of -36.10 and a beta of 5.29.

Insiders Place Their Bets

In related news, EVP Erik Phelps sold 9,464 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the completion of the transaction, the executive vice president owned 79,816 shares in the company, valued at $4,743,464.88. The trade was a 10.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the transaction, the executive vice president directly owned 126,918 shares of the company’s stock, valued at $7,654,424.58. The trade was a 7.94% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 590,109 shares of company stock valued at $37,056,566. Insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

Several institutional investors have recently bought and sold shares of the business. Cranbrook Wealth Management LLC purchased a new position in shares of Tempus AI during the 3rd quarter valued at approximately $25,000. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI during the third quarter worth about $26,000. GAMMA Investing LLC purchased a new stake in shares of Tempus AI during the third quarter worth about $28,000. Allworth Financial LP raised its position in shares of Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in Tempus AI in the 4th quarter valued at about $27,000. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.